Payment overview · 2025
General Payments
$381.09
16 reported records · 8 companies
Healthcare provider profile · identity verified
Sidharth C Patel, MD
Allopathic & Osteopathic Physicians|Family Medicine · ANDERSON, SC · NPI 1457306136
Verified facts
What the public records show
CMS Open Payments records show Sidharth C Patel, MD received $381.09 in general payments during 2025 across 16 reported records.
Lilly USA, LLC accounted for 39.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $150.19 | 39.4% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $101.39 | 26.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.31 | 10.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.93 | 6.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.81 | 5.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.28 | 4.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.54 | 4.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $13.64 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $381.09 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $107.46 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $101.39 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $42.73 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.04 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $12.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 108 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 332 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 221 | 88 |
| Atorvastatin Calcium | Atorvastatin Calcium | 201 | 76 |
| Metformin Hcl Er | Metformin Hcl | 197 | 66 |
| Lisinopril | Lisinopril | 184 | 72 |
| Losartan Potassium | Losartan Potassium | 158 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 154 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 150 | 54 |
| Alprazolam | Alprazolam | 135 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 50 |
| Clonazepam | Clonazepam | 116 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 112 | 24 |
| Omeprazole | Omeprazole | 112 | 44 |
| Ozempic | Semaglutide | 108 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 105 | 42 |
| Glipizide Er | Glipizide | 104 | 42 |
| Potassium Chloride | Potassium Chloride | 102 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 81 | 28 |
| Simvastatin | Simvastatin | 80 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 28 |
| Diazepam | Diazepam | 77 | 16 |
| Furosemide | Furosemide | 72 | 28 |
| Lorazepam | Lorazepam | 72 | 19 |
| Prednisone | Prednisone | 70 | 54 |
| Trazodone Hcl | Trazodone Hcl | 69 | 22 |
| Carvedilol | Carvedilol | 67 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 26 |
| Gabapentin | Gabapentin | 66 | 24 |
| Famotidine | Famotidine | 59 | 25 |
| Tramadol Hcl | Tramadol Hcl | 58 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 21 |
| Allopurinol | Allopurinol | 51 | 18 |
| Meloxicam | Meloxicam | 51 | 22 |
| Metformin Hcl | Metformin Hcl | 48 | 16 |
| Amoxicillin | Amoxicillin | 47 | 41 |
| Sertraline Hcl | Sertraline Hcl | 47 | 17 |
| Mounjaro | Tirzepatide | 44 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 20 |
| Montelukast Sodium | Montelukast Sodium | 43 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 12 |
| Ezetimibe | Ezetimibe | 35 | 11 |
| Alendronate Sodium | Alendronate Sodium | 34 | 18 |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 32 | 12 |
| Clonidine Hcl | Clonidine Hcl | 32 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 25 |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Valsartan | Valsartan | 30 | 12 |
| Azithromycin | Azithromycin | 29 | 27 |
| Lovastatin | Lovastatin | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | 11 |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Eliquis | Apixaban | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | 12 |
| Jardiance | Empagliflozin | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $381.09 · 16 records | Lilly USA, LLC | INSPIRE, JARDIANCE, Kerendia, MOUNJARO, OTEZLA, Ozempic, REPATHA, TRELEGY ELLIPTA, VRAYLAR, XIFAXAN, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error